SCHEDULE: Novo Holdings Discloses 5.3% Stake in Evotec SE

Novo Holdings A/S, an investment firm, has disclosed a 5.3% beneficial ownership stake in Evotec SE, holding 9,407,883 ordinary shares.

Summary

• Novo Holdings A/S reported beneficial ownership of 9,407,883 ordinary shares of Evotec SE.
• This represents 5.3% of Evotec SE's class of securities.
• Novo Holdings A/S holds sole voting power and sole dispositive power over all 9,407,883 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, with the event date requiring the filing being September 30, 2025.
• Novo Holdings A/S is a Danish investment firm focused on life sciences and finance, wholly owned by the Novo Nordisk Foundation.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional investment by a reputable life sciences firm, which is generally a positive signal for the issuer. However, as a routine ownership disclosure, it lacks specific operational or financial news to drive a higher score.

Positives

• A significant, long-term oriented life sciences investor, Novo Holdings A/S, maintains a substantial 5.3% stake in Evotec SE, indicating continued confidence in the company.
• Novo Holdings A/S retains sole voting and dispositive power over its 9,407,883 shares, providing clear control over its investment.

Negatives

• The filing, being a routine ownership disclosure, does not inherently contain negative operational or financial news for Evotec SE.

Risks

• No specific risks related to Evotec SE's operations or financial health are disclosed in this ownership filing.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Evotec SE's future performance or strategic direction.

Industry Context

Novo Holdings A/S is a prominent investment firm within the life sciences sector, known for its strategic investments in biotechnology and pharmaceutical companies. Its continued significant stake in Evotec SE, a drug discovery and development company, underscores the ongoing investor interest and potential perceived value within the broader life sciences industry, particularly in companies focused on R&D and therapeutic innovation.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially reinforcing confidence in the company.
• Management: Awareness of a major shareholder's position and potential influence.

Key Dates

Keywords

Evotec SE, Novo Holdings A/S, Schedule 13G, Beneficial Ownership, Life Sciences Investment, Biotechnology, Pharmaceuticals, Institutional Investor, SEC Filing, Stake Disclosure